{
    "clinical_study": {
        "@rank": "107430", 
        "acronym": "ARIQUELI", 
        "arm_group": [
            {
                "arm_group_label": "Lithium", 
                "arm_group_type": "Experimental", 
                "description": "Potentiation of previous treatment (Quetiapine monotherapy) with Lithium (0.5 - 0.8 mEq/L)"
            }, 
            {
                "arm_group_label": "Aripiprazole", 
                "arm_group_type": "Experimental", 
                "description": "Potentiation of previous treatment (Quetiapine monotherapy) with Aripiprazole (10 - 15 mg)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether Bipolar I Disorder refractory treatment\n      with Quetiapine monotherapy could be better potentiated with Lithium or Aripiprazole. The\n      investigators hypothesized that Lithium or Aripiprazole would provide similar compliance and\n      tolerability in maintenance treatment."
        }, 
        "brief_title": "Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Bipolar I Disorder", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of Bipolar Disorder, type I, in current episode (manic/hypomanic,\n             mixed or depression)\n\n          -  The patient or his (her) legal representative should understand the nature of the\n             study and sign the Informed Consent\n\n        Exclusion Criteria:\n\n          -  Schizophrenia or schizoaffective disorder\n\n          -  Mental retardation\n\n          -  Unstable clinical diseases"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710163", 
            "org_study_id": "ARIQUELI"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lithium", 
                "description": "Starting at 300 mg daily, weekly dose will be adjusted according to blood serum level (between 0.5 -0.8mEq/l) according to efficacy and tolerability.", 
                "intervention_name": "Lithium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Aripiprazole", 
                "description": "Starting at 10 mg daily, dose will be adjusted up to 15 mg daily according to efficacy and tolerability.", 
                "intervention_name": "Aripiprazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antidepressive Agents", 
                "Lithium Carbonate", 
                "Central Nervous System Agents", 
                "Lithium", 
                "Quetiapine", 
                "Aripiprazole", 
                "Central Nervous System Depressants", 
                "Antipsychotic Agents", 
                "Tranquilizing Agents", 
                "Neurotransmitter Agents", 
                "Sensory System Agents", 
                "Molecular Mechanisms of Pharmacological Action", 
                "Physiological Effects of Drugs"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lithium Carbonate", 
            "Lithium", 
            "Central Nervous System Agents", 
            "Therapeutic Uses", 
            "Pharmacologic Actions", 
            "Enzyme Inhibitors", 
            "Molecular Mechanisms of Pharmacological Action", 
            "Neurotransmitter Agents", 
            "Physiological Effects of Drugs", 
            "Antimanic Agents", 
            "Tranquilizing Agents", 
            "Central Nervous System Depressants", 
            "Psychotropic Drugs", 
            "Sensory System Agents", 
            "Antipsychotic Agents", 
            "Antidepressive Agents"
        ], 
        "lastchanged_date": "October 16, 2012", 
        "location": [
            {
                "contact": {
                    "email": "gmissio@mac.com", 
                    "last_name": "Giovani Missio", 
                    "phone": "+55 11 26616648"
                }, 
                "contact_backup": {
                    "email": "rmoreno@sti.com.br", 
                    "last_name": "Ricardo Alberto Moreno, MD, PhD", 
                    "phone": "+55 11 26616648"
                }, 
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil", 
                        "zip": "05403-010"
                    }, 
                    "name": "Institute of Psychiatry, University of S\u00e3o Paulo"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Missio"
                }, 
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil", 
                        "zip": "05403010"
                    }, 
                    "name": "Institute of Psychiatry"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "ARIQUELI: Potentiation of Quetiapine Treatment in Bipolar 1 Nonresponders Patients With Lithium or Aripiprazole", 
        "overall_contact": {
            "email": "gmissio@mac.com", 
            "last_name": "Giovani Missio", 
            "phone": "+ 55 11 2661 6648"
        }, 
        "overall_contact_backup": {
            "email": "rmoreno@sti.com.br", 
            "last_name": "Ricardo Alberto Moreno, MD, PhD", 
            "phone": "+ 55 11 2661 6648"
        }, 
        "overall_official": [
            {
                "affiliation": "Institute of Psychiatry, University of S\u00e3o Paulo", 
                "last_name": "Ricardo Alberto Moreno, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institute of Psychiatry, University of S\u00e3o Paulo", 
                "last_name": "Giovani Missio, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The main outcome will be the number of patients that achieve and remain in remission to each treatment at the end of each phase of the study", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710163"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Sao Paulo", 
            "investigator_full_name": "Ricardo Alberto Moreno, M.D., Ph.D.", 
            "investigator_title": "MD PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Sao Paulo", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Sao Paulo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}